313 related articles for article (PubMed ID: 27335205)
1. Public-Private Partnerships in Lead Discovery: Overview and Case Studies.
Gottwald M; Becker A; Bahr I; Mueller-Fahrnow A
Arch Pharm (Weinheim); 2016 Sep; 349(9):692-7. PubMed ID: 27335205
[TBL] [Abstract][Full Text] [Related]
2. Towards a European strategy for medicines research (2014-2020): The EUFEPS position paper on Horizon 2020.
Gaspar R; Aksu B; Cuine A; Danhof M; Takac MJ; Linden HH; Link A; Muchitsch EM; Wilson CG; Ohrngren P; Dencker L
Eur J Pharm Sci; 2012 Dec; 47(5):979-87. PubMed ID: 23046836
[TBL] [Abstract][Full Text] [Related]
3. The innovative medicines initiative: a European response to the innovation challenge.
Goldman M
Clin Pharmacol Ther; 2012 Mar; 91(3):418-25. PubMed ID: 22318619
[TBL] [Abstract][Full Text] [Related]
4. Drugs for Neglected Diseases initiative model of drug development for neglected diseases: current status and future challenges.
Ioset JR; Chang S
Future Med Chem; 2011 Sep; 3(11):1361-71. PubMed ID: 21879842
[TBL] [Abstract][Full Text] [Related]
5. Open-access public-private partnerships to enable drug discovery--new approaches.
Müller S; Weigelt J
IDrugs; 2010 Mar; 13(3):175-80. PubMed ID: 20191434
[TBL] [Abstract][Full Text] [Related]
6. The impact of assay technology as applied to safety assessment in reducing compound attrition in drug discovery.
Thomas CE; Will Y
Expert Opin Drug Discov; 2012 Feb; 7(2):109-22. PubMed ID: 22468913
[TBL] [Abstract][Full Text] [Related]
7. U-BIOPRED: evaluation of the value of a public-private partnership to industry.
Riley JH; Erpenbeck VJ; Matthews JG; Holweg CTJ; Compton C; Seibold W; Higenbottam T; Wagers S; Rowe A; Myles D;
Drug Discov Today; 2018 Sep; 23(9):1622-1634. PubMed ID: 29936248
[TBL] [Abstract][Full Text] [Related]
8. Public-private partnership models in France and in Europe.
Demotes-Mainard J; Canet E; Segard L
Therapie; 2006; 61(4):325-34, 313-23. PubMed ID: 17124948
[TBL] [Abstract][Full Text] [Related]
9. [The Innovative Medicine Initiative (IMI)].
Bril A; Canet E
Med Sci (Paris); 2008 Oct; 24(10):885-90. PubMed ID: 18950588
[TBL] [Abstract][Full Text] [Related]
10. Open PHACTS: semantic interoperability for drug discovery.
Williams AJ; Harland L; Groth P; Pettifer S; Chichester C; Willighagen EL; Evelo CT; Blomberg N; Ecker G; Goble C; Mons B
Drug Discov Today; 2012 Nov; 17(21-22):1188-98. PubMed ID: 22683805
[TBL] [Abstract][Full Text] [Related]
11. The Innovative Medicines Initiative's New Drugs for Bad Bugs programme: European public-private partnerships for the development of new strategies to tackle antibiotic resistance.
Kostyanev T; Bonten MJ; O'Brien S; Steel H; Ross S; François B; Tacconelli E; Winterhalter M; Stavenger RA; Karlén A; Harbarth S; Hackett J; Jafri HS; Vuong C; MacGowan A; Witschi A; Angyalosi G; Elborn JS; deWinter R; Goossens H
J Antimicrob Chemother; 2016 Feb; 71(2):290-5. PubMed ID: 26568581
[TBL] [Abstract][Full Text] [Related]
12. Leveraging public private partnerships to innovate under challenging budget times.
Portilla LM; Rohrbaugh ML
Curr Top Med Chem; 2014; 14(3):326-9. PubMed ID: 24283971
[TBL] [Abstract][Full Text] [Related]
13. The Importance of Collaboration between Industry, Academics, and Nonprofits in Tropical Disease Drug Discovery.
Ferrins L; Pollastri MP
ACS Infect Dis; 2018 Apr; 4(4):445-448. PubMed ID: 29134797
[TBL] [Abstract][Full Text] [Related]
14. Public-private partnerships to revitalize psychiatric drug discovery.
Brady LS; Potter WZ
Expert Opin Drug Discov; 2014 Jan; 9(1):1-8. PubMed ID: 24308355
[TBL] [Abstract][Full Text] [Related]
15. Open innovation platforms to boost pharmaceutical collaborations: evaluating external compounds for desired biological activity.
Nilsson N; Felding J
Future Med Chem; 2015; 7(14):1853-9. PubMed ID: 26393392
[No Abstract] [Full Text] [Related]
16. Promoting drug discovery by collaborative innovation: a novel risk- and reward-sharing partnership between the German Cancer Research Center and Bayer HealthCare.
Wellenreuther R; Keppler D; Mumberg D; Ziegelbauer K; Lessl M
Drug Discov Today; 2012 Nov; 17(21-22):1242-8. PubMed ID: 22521665
[TBL] [Abstract][Full Text] [Related]
17. The Innovative Medicines Initiative: an engine for regulatory science.
Goldman M; Seigneuret N; Eichler HG
Nat Rev Drug Discov; 2015 Jan; 14(1):1-2. PubMed ID: 25503331
[TBL] [Abstract][Full Text] [Related]
18. Kinetics for Drug Discovery: an industry-driven effort to target drug residence time.
Schuetz DA; de Witte WEA; Wong YC; Knasmueller B; Richter L; Kokh DB; Sadiq SK; Bosma R; Nederpelt I; Heitman LH; Segala E; Amaral M; Guo D; Andres D; Georgi V; Stoddart LA; Hill S; Cooke RM; De Graaf C; Leurs R; Frech M; Wade RC; de Lange ECM; IJzerman AP; Müller-Fahrnow A; Ecker GF
Drug Discov Today; 2017 Jun; 22(6):896-911. PubMed ID: 28412474
[TBL] [Abstract][Full Text] [Related]
19. Public-Private Partnerships: Compound and Data Sharing in Drug Discovery and Development.
Davis AM; Engkvist O; Fairclough RJ; Feierberg I; Freeman A; Iyer P
SLAS Discov; 2021 Jun; 26(5):604-619. PubMed ID: 33586501
[TBL] [Abstract][Full Text] [Related]
20. Leveraging crowdsourcing to facilitate the discovery of new medicines.
Norman TC; Bountra C; Edwards AM; Yamamoto KR; Friend SH
Sci Transl Med; 2011 Jun; 3(88):88mr1. PubMed ID: 21697527
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
